All In Biotech

Drug Trial Radar · NCT07221513

Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension

A Phase 2a, Open-Label Study to Assess the Safety, Tolerability, and Efficacy of JK07 in Participants With Heart Failure and Group 2 Combined Post-Capillary and Pre-Capillary Pulmonary Hypertension (RENEU-PH)

Last checked: Nov 19, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Dec 15, 2025

Primary completion

Apr 16, 2026

Study completion Apr 16, 2026

Sponsor

Lead sponsor
Salubris Biotherapeutics IncIndustry
Sponsor type
Industry
First posted
Oct 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2a, open-label, multiple-dose study to assess the safety, tolerability, and efficacy of JK07 in participants 18 to 85 years of age with diagnosed HF and cpcPH. At least 20 and up to approximately 30 participants will be enrolled and receive JK07 high dose in this open-label trial.

Conditions

  • HFrEF - Heart Failure With Reduced Ejection Fraction
  • HFpEF - Heart Failure With Preserved Ejection Fraction
  • Group 2 Pulmonary Hypertension

Interventions

  • JK07Drug

    JK07 is a fully human anti-human epidermal growth factor receptor 3 (also known as ErbB3 or HER3) antibody fused with the epidermal growth factor (EGF)-domain of Neuregulin (NRG)-1b protein.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of TEAEs [Safety and tolerability]Time frame: Study entry through week 26

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Saint Francis Heart and Vascular Institute

    Tulsa, Oklahoma

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.